Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vinpocetine Dose-Escalation in Healthy Volunteers
NCT06635746Phase 1Not yet recruiting
- Sponsor
- Stanford University
- Start
- Jun 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of vinpocetine in cognitive impairment and Fetal Alcohol Spectrum Disorders (FASDs), sponsored by Stanford University. Primary endpoint: Adverse Events. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
vinpocetine
03
Conditions
cognitive impairmentFetal Alcohol Spectrum Disorders (FASDs)
Beyond the preview
Go deeper on NCT06635746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06635746.